Skip to main
RCEL

RCEL Stock Forecast & Price Target

RCEL Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

AVITA Medical reported a full-year revenue of approximately $71.6 million for 2025, which marks an 11% increase from $64.3 million in 2024 and aligns with the company's revised guidance. The company experienced an improvement in net cash use, decreasing from about $6.2 million in the third quarter to approximately $5.1 million, indicating enhanced financial efficiency. Additionally, management’s revenue guidance for 2026, projected between $80 million and $85 million, reflects anticipated commercial momentum driven by deeper market penetration and the integration of its product portfolio.

Bears say

AVITA Medical's revenue expectations have been lowered, leading to a significant reduction in target valuation from $14.0 to $10.0. The company reported a net loss of $11.6 million, equating to $0.38 per share, which remains unchanged compared to the prior year period when the loss was $11.6 million or $0.44 per share. Additionally, despite its innovative RECELL system being utilized in US burn centers, the limited marketing efforts abroad and reliance on a single product could pose challenges for future growth.

RCEL has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AVITA Medical Inc (RCEL) Forecast

Analysts have given RCEL a Buy based on their latest research and market trends.

According to 3 analysts, RCEL has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AVITA Medical Inc (RCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.